Fig. S1. This Forest plot shows the 95% CrI for the equivalence between the biosimilar and the originator (in red) along with the 95% CrI showing the inferiority of the SOC compared with the originator (in green) and with the 95% CrI showing the inferiority of the SOC compared with the biosimilar (in brown). Odds ratio is the outcome measured. The end-point is ACR50 at 24-26 weeks. The dashed vertical lines indicate the two post-hoc margins of equivalence.

Complete references for the randomised trials reported in Table I.


